Skip to main content
SpringerLink
Log in

„Low-dose“-Theophyllin zur Prävention von Exazerbationen bei COPD-Patienten – Eine sinnvolle Therapie?

Low-dose theophylline for prevention of exacerbations in COPD patients—A meaningful treatment?

  • Journal Club
  • Published:
Der Pneumologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, Singh D (2018) Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. https://doi.org/10.1016/S0140-6736(18)30206-X

  2. Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ, Investigators I (2018) Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med 378:1671–1680

    Article  CAS  Google Scholar 

  3. Wedzicha JA, Rabe KF, Martinez FJ, Bredenbroker D, Brose M, Goehring UM, Calverley PM (2013) Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest 143:1302–1311

    Article  CAS  Google Scholar 

  4. Vogelmeier C, Buhl R, Burghuber O, Criee CP, Ewig S, Godnic-Cvar J, Hartl S, Herth F, Kardos P, Kenn K, Nowak D, Rabe KF, Studnicka M, Watz H, Welte T, Windisch W, Worth H (2018) unter Mitwirkung der folgenden wissenschaftlichen Fachgesellschaften: Deutsche Gesellschaft fur Arbeitsmedizin und Umweltmedizin e V, Deutsche Gesellschaft fur Rehabilitationswissenschaften e V: [Guideline for the Diagnosis and Treatment of COPD Patients—Issued by the German Respiratory Society and the German Atemwegsliga in Cooperation with the Austrian Society of Pneumology. Pneumologie 72:253–308

    Article  CAS  Google Scholar 

  5. Cosio BG, Iglesias A, Rios A, Noguera A, Sala E, Ito K, Barnes PJ, Agusti A (2009) Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of chronic obstructive pulmonary disease. Thorax 64(5):424–429

    Article  CAS  Google Scholar 

  6. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ (2004) Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 200:689–695

    Article  CAS  Google Scholar 

  7. Barnes PJ (2013) Theophylline. Am J Respir Crit Care Med 188:901–906

    Article  CAS  Google Scholar 

  8. Ford PA, Durham AL, Russell RE, Gordon F, Adcock IM, Barnes PJ (2010) Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest 137:1338–1344

    Article  CAS  Google Scholar 

  9. Zhou Y, Wang X, Zeng X, Qiu R, Xie J, Liu S, Zheng J, Zhong N, Ran P (2006) Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology 11:603–610

    Article  Google Scholar 

  10. Cosio BG, Shafiek H, Iglesias A, Yanez A, Cordova R, Palou A, Rodriguez-Roisin R, Peces-Barba G, Pascual S, Gea J, Sibila O, Barnes PJ, Agusti A (2016) Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial. Chest 150:123–130

    Article  Google Scholar 

  11. Devereux G, Cotton S, Fielding S, McMeekin N, Barnes PJ, Briggs A, Burns G, Chaudhuri R, Chrystyn H, Davies L, De Soyza A, Gompertz S, Haughney J, Innes K, Kaniewska J, Lee A, Morice A, Norrie J, Sullivan A, Wilson A, Price D (2018) Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial. JAMA 320:1548–1559

    Article  CAS  Google Scholar 

  12. Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF (2015) Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 385:857–866

    Article  CAS  Google Scholar 

  13. Vestbo J (2016) the Salford Lung Study I: Effectiveness of Fluticasone Furoate-Vilanterol in COPD. N Engl J Med 375:2607

    Article  Google Scholar 

  14. Buhl R, Criee CP, Kardos P, Vogelmeier C, Lossi N, Mailander C, Worth H (2016) A year in the life of German patients with COPD: the DACCORD observational study. Int J Chron Obstruct Pulmon Dis 11:1639–1646

    Article  Google Scholar 

  15. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID (2015) Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 3:435–442

    Article  CAS  Google Scholar 

  16. Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, Wedzicha JA, Singh D (2015) Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 192:523–525

    Article  Google Scholar 

  17. Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, Fageras M (2018) Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med 6(2):117–126

    Article  CAS  Google Scholar 

  18. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2019 report). www.goldcopd.org/gold-reports/

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin, SP Pneumologie, UKGM Marburg, Baldingerstraße, 35043, Marburg, Deutschland

    Timm Greulich

Authors
  1. Timm Greulich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timm Greulich.

Ethics declarations

Interessenkonflikt

T. Greulich hat von CSL-Behring, DZL und Grifols Forschungsunterstützung erhalten. Für Astra Zeneca, Berlin-Chemie, Ingelheimer, Chiesi, CSL-Behring, Grifols, GSK und Novartis hat er Vorträge gehalten oder an Advisory Boards und Kongressen teilgenommen.

Additional information

Redaktion

J. Schreiber, Magdeburg

P. Zabel, Lübeck/Borstel

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Greulich, T. „Low-dose“-Theophyllin zur Prävention von Exazerbationen bei COPD-Patienten – Eine sinnvolle Therapie?. Pneumologe 16, 104–106 (2019). https://doi.org/10.1007/s10405-019-0235-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10405-019-0235-9

Search

Navigation